Agile Therapeutics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Agile Therapeutics is a commercial-stage biopharmaceutical company dedicated to providing women with expanded contraceptive options. The company's primary asset is Twirla, a hormonal contraceptive patch utilizing its Skinfusion® transdermal technology, which represents its first approved product. Founded in 1997 and headquartered in Princeton, New Jersey, Agile is publicly traded and operates in the small molecules sector. Its pipeline and commercial strategy are centered on leveraging its proprietary patch platform to address unmet needs in women's health.

Women's HealthContraception

Technology Platform

Skinfusion® transdermal patch technology designed for improved drug delivery and wearability.

Opportunities

The large, established contraceptive market offers a significant opportunity for a well-differentiated product.

Agile's Skinfusion® technology, validated by Twirla's approval, provides a platform to develop additional convenient hormonal therapies for women's health, potentially addressing unmet needs.

Risk Factors

The company faces extreme concentration risk as it relies solely on the commercial success of Twirla.

Key risks include slow market adoption, challenges with payer reimbursement, competition from numerous other contraceptive methods, and the financial strain of commercializing a product with a limited cash runway.

Competitive Landscape

Twirla competes in a crowded contraceptive market against oral pills, other transdermal patches (e.g., Xulane), vaginal rings, implants, and intrauterine devices (IUDs). Its differentiation is based on its proprietary patch technology aimed at wearability, but it faces competition from both generic and branded products with longer track records.

More companies in Small Molecule Drugs →More companies in United States →